GSK says RSV vaccine for older adults provides protection over two seasons

GlaxoSmithKline’s vaccine to protect adults ages 60 and older from respiratory syncytial virus, or RSV, remained effective across two seasons, the company said.
New phase three clinical trial results suggest seniors may only need to take the RSV vaccine every other year.